Use the select box drop down menus below to filter research funding announcements by "Agency" or by "Application Due Date"

or

LBDA Policy on Indirect Rates

Grant proposals to LBDA should not exceed a 10% indirect rate; this is the maximum allowed for the primary applicant organization and any sub-grantees or contractors. (If a grantee has an indirect cost rate lower than 10%, they should not increase the funding to the maximum allowed.) LBDA reserves the right to allow for a higher indirect rate in rare situations as warranted. Written permission from LBDA’s contact person for the grant opportunity is required in advance of submitting a proposal with an indirect rate higher than 10%.

Stay up-to-date on LBD-relevant funding opportunity announcements from LBDA and federal agencies like the National Institutes of Health and Department of Defense.

Lewy Body Dementia Association Mentorship Program Award

The goal of this program is to promote the continued development of newly trained clinician-researchers, or experienced clinician-researchers new to LBD, into world-class LBD investigators. This might include individuals with fellowship training in movement disorders, behavioral neurology, geriatric psychiatry, or geriatric medicine. The initiative focuses on the mentorship of young or experienced investigators committed to clinical research in the Lewy body dementia arena by seasoned, established LBD investigators.

Full details, including requirements for the mentees, mentee projects, and mentors are available on the Request for Applications.

Mentees must complete and submit the Mentee Application.

 

APPLICATION DUE DATE:

A .PDF copy of the completed Mentee Application must be received via email by LBDA on or before Friday, Dec. 3, 2021, by 11:59 p.m. Eastern Daylight Time.

Lewy Body Dementia Association (LBDA)
09/13/2021
12/03/2021

LBDA will fund up to 4 mentee awards.

$4,000 (including up to a maximum of 10% indirect costs) for the mentee’s proposed project and/or mentee conference/travel costs. Mentors will be offered a $2,000 honorarium

1 year

Angela Taylor
814-826-4150
ataylor@LBDA.org

Learn More Close

Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit studies that will advance the mechanistic understanding of small vessel vascular contributions to cognitive impairment and dementia (VCID) through the development of new technologies and innovative methods that enable the imaging and/or functional assessment of the small blood and lymphatic vessels and perivascular spaces of the brain.

This program aims to facilitate the development of tools and technology to image, profile and/or mechanistically characterize CNS small blood and lymphatic vessels in Alzheimer’s Disease and Alzheimer’s Disease-Related Dementia (AD/ADRD) animal models or patient populations. The overall goal is to use such technologies or methods to elucidate the mechanisms that link CNS small blood and lymphatic vessel dysfunction to dementia outcomes in the AD/ADRDs, their potential role in repair processes, and their response to therapies. Preclinical studies of small vessel VCID in vitro and/or animal models and pilot human subject studies (that do not meet the NIH definition of clinical trial) are appropriate for this FOA.

PAR-22-026
National Institute of Neurological Disorders and Stroke (NINDS)
10/08/2021
10/08/2021
11/08/2021

NINDS intends to commit $6,500,000 total costs per year in FY 2022-2027 to fund five awards. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets are limited to $499,000 direct costs/year and need to reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is five years.

Francesca Bosetti, Pharm.D., Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1431
Email: frances@mail.nih.gov

William Daley, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1431
Email: william.daley@nih.gov

Mack Mackiewicz, Ph. D.
National Institute on Aging (NIA)
Phone: 301-496-9350
Email: miroslaw.mackiewicz@nih.gov

Learn More Close

Notice of Special Interest (NOSI): Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research

The goal of this Notice of Special Interest (NOSI) is to encourage the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan (e.g., Alzheimer’s disease and Alzheimer's disease-related dementias (AD/ADRD)), (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health (the hallmarks of aging). Activities of high priority include those addressing specific hypotheses in basic biological research, clinical aging research, behavioral or social research, and/or translational geroscience to inform: the design and implementation of future epidemiologic or human intervention studies; interventions in animal models of aging; research on behavioral and social factors over the life course that influence health (e.g., early life adversity); current geriatric practice in maintenance of health, disease management, and prevention of disability; or research testing of possible causal relationships between rates of aging and findings extracted by secondary analysis of the existing data. Existing datasets may also be used to develop and test new mathematical modeling and statistical analytical approaches. Analyses of sex and/or gender differences across health disparity groups (e.g., racial and ethnic groups, socioeconomic status, and sexual and gender minorities) are of high relevance. Use of cohorts that are linked to electronic health record systems and/or Centers for Medicare and Medicaid Services (CMS) administrative data are especially welcome.

NOT-AG-21-020
National Institute on Aging (NIA)

See https://grants.nih.gov/grants/guide/notice-files/NOT-AG-21-020.html for details.

Learn More Close

Multi-Disciplinary Collaborations to Understand Mechanisms of Systemic Immune Signaling and Inflammation in ADRD and its Progression (R01 Clinical Trial Not Allowed)

Recent findings have raised the hypothesis that systemic immune responses could play direct or indirect roles in brain neurodegeneration leading to AD/ADRD and have been significantly less studied than immune responses confined exclusively to within the brain parenchyma. The purpose of this funding opportunity announcement (FOA) is to support partnerships and new collaborations between neuroscientists and immunologists to expand the research base in this area with the long-term goal of bringing more immunology expertise into the AD/ADRD field and to support further work in this area through investigator-initiated and other mechanisms.

PAR-22-023
Office of The Director, National Institutes of Health (OD)
09/22/2021
10/22/2021

NINDS intends to commit $3,750,000 in total costs per year in FY2022-2027 to fund up to five awards contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets are limited to $499,000 direct costs/year and need to reflect the actual needs of the proposed project.

The maximum project period is five years.

Tom Cheever, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-5680
Email: thomas.cheever@nih.gov

Mack Mackiewicz, Ph. D.
National Institute on Aging (NIA)
Phone: 301-496-9350
Email: miroslaw.mackiewicz@nih.gov

Learn More Close

Pragmatic Trials for Dementia Care and Caregiver Support (R61/R33 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings that will: (1) be designed to address practical comparative questions faced by Alzheimer’s disease (AD) and AD-related dementia (ADRD) patients, clinicians, and caregivers (both paid and unpaid); (2) include broad and diverse populations; and (3) be conducted in real-world settings with adequate sample size. These trials are intended to produce results that can be directly adopted by healthcare providers, patients, or caregivers for rapid dissemination and implementation. Successful applications will: (1) improve quality of care of persons with dementia; (2) improve quality of life for persons with dementia and their informal caregivers; (3) deliver more patient-focused, cost-effective care across multiple settings; and/or (4) reduce disparities in dementia care.

This FOA will support Stage I or Stage III pilot research to test the feasibility of implementing and integrating interventions (R61 phase) that, if successful, can transition to an R33 phase (Stage IV) for implementation of large pragmatic trials.

The transition from the R61 to the R33 phase of the award will be administratively reviewed and determined by successful completion of the go/no-go criteria that are specified for the R61 phase.

PAR-21-308
Office of The Director, National Institutes of Health (OD)

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

For the R61 planning phase, the combined budget for direct costs for up to two years may not exceed $500,000.

For the R33 phase, budgets are expected to go over $500,000. Applicants requesting $500,000 or more in direct costs during the R33 phase in any year (excluding consortium F&A) must contact a Scientific/Research Contact at least 6 weeks before submitting the application.

The scope of the proposed project should determine the project period. It is expected that the R61 phase will occur during the first 1- 2 years. Researchers who complete R61 development work are encouraged to apply to R61 transition to the R33 implementation phase in pragmatic trials for the remaining 2-4 years of the grant. The maximum period of the combined R61 and R33 phases is 5 years.

Partha Bhattacharyya, Ph. D.
National Institute on Aging (NIA)
Telephone: 301-496-3136
Email: bhattacharyyap@mail.nih.gov

Learn More Close

Dementia Care and Caregiver Support Intervention Research (R01 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD) and of those providing their care. The NIH Stage Model offers a framework to: (1) support development of efficacious interventions that are defined by their principles; and (2) ensure that these efficacious interventions can be administered in the community or in health systems with fidelity to the intervention’s principles. This includes the development, testing, and validation of scalable training materials and procedures so that these interventions can be delivered with fidelity in community settings or health systems. Settings can include the home, community, or formal care settings, such as nursing homes, assisted living facilities, nursing and rehabilitation centers, hospitals, adult day care, and specialized hospice settings. The overarching purpose of this FOA is to help to lay the groundwork for real-world implementation of AD/ADRD care and caregiving interventions.

PAR-21-307
National Institute on Aging (NIA)

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Lisa Onken, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-3136
Email: lisa.onken@nih.gov

Learn More Close

Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)

The purpose of this funding opportunity is to support projects to identify cellular changes in ADRD post-mortem brain tissue across disease progression. Applicants are encouraged to propose single-nucleus transcriptomic and epigenomic studies that identify changes in neuronal, glial, or vascular cells over multiple ADRD stages, from early to mid-stage. All sequencing data and any available pre-mortem clinical data will be broadly shared with the research community.

PAR-22-029
Office of The Director, National Institutes of Health (OD)

NINDS intends to commit $3.8M in total costs in FY2022 for up to four awards.

Application budgets are limited to $630,000 direct costs/year and need to reflect the actual needs of the proposed project.

The maximum project period is 5 years.

Daniel Miller, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-5680
Email: daniel.miller@nih.gov

Mack Mackiewicz, Ph. D.
National Institute on Aging (NIA)
Phone: 301-496-9350
Email: miroslaw.mackiewicz@nih.gov

Learn More Close

Leveraging Existing Data Resources for Computational Model and Tool Development to Discover Novel Candidate Mechanisms and Biomarkers for ADRD (R01 Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement is to expand the use of existing ADRD data resources to drive, via computational model development and dissemination, new discoveries that can lead to better understanding of mechanisms, clinical risk assessment and outcomes, and to identify novel candidate biomarkers for ADRD.

RFA-NS-22-006
Office of The Director, National Institutes of Health (OD)
10/26/2021

NINDS intends to commit $6,500,000 total costs per year in FY 2022-2027 to fund up to five awards contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets are limited to $499,000 direct costs/year and need to reflect the actual needs of the proposed project.

The maximum project period is five years.

Tom Cheever, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-5680
Email: thomas.cheever@nih.gov

Jean Yuan, Ph. D.
National Institute on Aging (NIA)
Phone: 301-496-9350
Email: xin.yuan@nih.gov

Learn More Close

Biomarkers for the Lewy Body Dementias (U01 Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven clinical research applications that are focused on discovering novel diagnostic, prognostic, and/or therapeutic biomarkers for the Lewy Body Dementias (LBD). Biomarker research must be conducted in patients with LBD, must follow Parkinson's Disease Biomarker Program (PDBP) protocols for clinical assessment and biospecimen collection, and must be broadly shareable through the PDBP repositories.

RFA-NS-22-001
Office of The Director, National Institutes of Health (OD)
09/22/2021
10/22/2021

NINDS intends to commit $3,500,000 TC in FY 2022 to fund 3-6 awards.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Debra Babcock, PhD, MD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9964
Email: dbabcock@mail.nih.gov

Learn More Close

Lewy Body Dementia Association Mentorship Program Award

The goal of this program is to promote the continued development of newly trained clinician-researchers, or experienced clinician-researchers new to LBD, into world-class LBD investigators. This might include individuals with fellowship training in movement disorders, behavioral neurology, geriatric psychiatry, or geriatric medicine. The initiative focuses on the mentorship of young or experienced investigators committed to clinical research in the Lewy body dementia arena by seasoned, established LBD investigators.

Full details, including requirements for the mentees, mentee projects, and mentors are available on the Request for Applications.

Mentees must complete and submit the Mentee Application.

 

APPLICATION DUE DATE:

A .PDF copy of the completed Mentee Application must be received via email by LBDA on or before Friday, Dec. 3, 2021, by 11:59 p.m. Eastern Daylight Time.

Lewy Body Dementia Association (LBDA)
09/13/2021
12/03/2021

LBDA will fund up to 4 mentee awards.

$4,000 (including up to a maximum of 10% indirect costs) for the mentee’s proposed project and/or mentee conference/travel costs. Mentors will be offered a $2,000 honorarium

1 year

Angela Taylor
814-826-4150
ataylor@LBDA.org

Learn More Close

NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)

The objectives of the NIH Academic Leadership Career Award (K07) are to increase the pool of individuals with academic and research expertise in a specific area of biomedical research and to enhance the educational or research capacity at the grantee institution. The K07 Leadership Award provides support for senior investigators who are interested in improving the curricula and enhancing the health-related research capacity within an academic institution.

PAR-21-106
National Institute on Aging (NIA)
06/12/2021

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Award budgets are composed of salary and other program-related expenses, as described below.

The total project period may not exceed 5 years.

NIA Training Office
National Institute on Aging (NIA)
Email: NIAtraining@nih.gov

Learn More Close

NIA MSTEM: Advancing Diversity in Aging Research through Undergraduate Education (R25 – Independent Clinical Trial Not Allowed)

The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

PAR-20-317
Office of The Director, National Institutes of Health (OD)
04/25/2021
04/25/2023
05/25/2023

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Direct costs up to $375,000 per year may be requested.

The scope of the proposed project period should determine the project period. The maximum period is five years.

NIA Training Office
National Institute on Aging (NIA)
Email: NIAtraining@nih.gov

Learn More Close

NIA MSTEM: Advancing Diversity in Aging Research through Undergraduate Education (R25 – Independent Clinical Trial Not Allowed)

The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

PAR-20-317
Office of The Director, National Institutes of Health (OD)
04/25/2021
04/25/2022
05/25/2022

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Direct costs up to $375,000 per year may be requested.

The scope of the proposed project period should determine the project period. The maximum period is five years.

NIA Training Office
National Institute on Aging (NIA)
Email: NIAtraining@nih.gov

Learn More Close

NIA MSTEM: Advancing Diversity in Aging Research through Undergraduate Education (R25 – Independent Clinical Trial Not Allowed)

The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

PAR-20-317
Office of The Director, National Institutes of Health (OD)
04/25/2021
04/25/2021
05/25/2021

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Direct costs up to $375,000 per year may be requested.

The scope of the proposed project period should determine the project period. The maximum period is five years.

NIA Training Office
National Institute on Aging (NIA)
Email: NIAtraining@nih.gov

Learn More Close

NIA IMPACT Collaboratory – Career Development Award

These CDAs seek to support the development of early-stage MD, PhD, or equivalent researchers who seek careers conducting ePCTs for people living with AD/ADRD and their care partners. The IMPACT Collaboratory prioritizes applications that address dementia care for people of all backgrounds and promote health equity.

National Institute on Aging (NIA)
04/02/2021

Up to four awards

Each award will provide $100,000 annually in direct costs with an indirect cost rate capped at 8%. Awardees are required to devote a minimum of 75% effort toward the goals of the award.

Two years

Christopher M. Callahan, MD, MACP,
Training Core Leader
IMPACTcollaboratory@hsl.harvard.edu

Learn More Close

The Midlife in the United States Study – Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit an Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD)-focused U01 that is ancillary to, but integrated with, the Midlife in the United States Study (MIDUS) U19 (see PAR-21-156) to provide in-depth information to elucidate behavioral, social, psychological and biological pathways of risk and resilience to cognitive decline and AD/ADRD. In addition to capitalizing on already-collected data, new measures should be included to test hypotheses regarding development of AD/ADRD via cumulative stress exposures over 30 prior years of data collection. As well, the research should examine the protective influence of psychosocial resources, affective style, and lifestyle factors assessed over multiple prior waves of MIDUS. The new assessments on two national samples with many years of information on potential influences on AD/ADRD hold potential for yielding invaluable insights relevant for preventative interventions and treatments in future studies.

PAR-21-157
National Institute on Aging (NIA)
03/26/2021
03/26/2021
11/18/2021

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NIA intends to make one award pending the availability of funds.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 6 years.

Dana Jeffrey Plude, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-3136
Email: dana.plude@nih.gov

Learn More Close

The Midlife in the United States Study – Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit an Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD)-focused U01 that is ancillary to, but integrated with, the Midlife in the United States Study (MIDUS) U19 (see PAR-21-156) to provide in-depth information to elucidate behavioral, social, psychological and biological pathways of risk and resilience to cognitive decline and AD/ADRD. In addition to capitalizing on already-collected data, new measures should be included to test hypotheses regarding development of AD/ADRD via cumulative stress exposures over 30 prior years of data collection. As well, the research should examine the protective influence of psychosocial resources, affective style, and lifestyle factors assessed over multiple prior waves of MIDUS. The new assessments on two national samples with many years of information on potential influences on AD/ADRD hold potential for yielding invaluable insights relevant for preventative interventions and treatments in future studies.

PAR-21-157
National Institute on Aging (NIA)
03/26/2021
03/26/2021
04/26/2021

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NIA intends to make one award pending the availability of funds.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 6 years.

Dana Jeffrey Plude, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-3136
Email: dana.plude@nih.gov

Learn More Close

NINDS Institutional Research Training Program (T32 Clinical Trial Not Allowed)

The objective of the NINDS Institutional Research Training Program is to support outstanding training with the breadth and depth to prepare advanced predoctoral and postdoctoral trainees to become successful scientists in a rapidly evolving research enterprise that is increasingly complex and multidisciplinary.

PAR-21-149
National Institute of Neurological Disorders and Stroke (NINDS)
04/25/2021
05/25/2023

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets are not limited, but need to reflect the actual needs of the proposed project.

Up to 5 years

Stephen Korn, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Email: korns@ninds.nih.gov

Learn More Close

NINDS Institutional Research Training Program (T32 Clinical Trial Not Allowed)

The objective of the NINDS Institutional Research Training Program is to support outstanding training with the breadth and depth to prepare advanced predoctoral and postdoctoral trainees to become successful scientists in a rapidly evolving research enterprise that is increasingly complex and multidisciplinary.

PAR-21-149
National Institute of Neurological Disorders and Stroke (NINDS)
04/25/2021
05/25/2022

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets are not limited, but need to reflect the actual needs of the proposed project.

Up to 5 years

Stephen Korn, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Email: korns@ninds.nih.gov

Learn More Close

NINDS Institutional Research Training Program (T32 Clinical Trial Not Allowed)

The objective of the NINDS Institutional Research Training Program is to support outstanding training with the breadth and depth to prepare advanced predoctoral and postdoctoral trainees to become successful scientists in a rapidly evolving research enterprise that is increasingly complex and multidisciplinary.

PAR-21-149
National Institute of Neurological Disorders and Stroke (NINDS)
04/25/2021
05/25/2021

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets are not limited, but need to reflect the actual needs of the proposed project.

Up to 5 years

Stephen Korn, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Email: korns@ninds.nih.gov

Learn More Close

ADDF-HARRINGTON SCHOLAR PROGRAM

This unique award provides funding and committed project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute.

 

The 2021 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia, particularly epigenetics and proteostasis. Other novel targets are encouraged, such as neurovascular health, neuroprotection, synaptic activity and neurotransmitters, inflammation, mitochondria and metaboloic function, ApoE, other aging targets. NOTE: This RFP does not support anti-amyloid approaches (e.g. Abeta vaccines, beta- or gamma-secretase inhibitors) or cholinesterase inhibitors.

04/23/2021
07/30/2021

Up to $600,000 over 2 years

Two years

Alzheimer’s Drug Discovery Foundation
Meriel Owen, PhD
Assistant Director, Scientific Affairs
mowen@alzdiscovery.org

 

Harrington Discovery Institute
Bronwyn J. Monroe
Director, Programs
bronwyn.monroe@harringtondiscovery.org

Learn More Close

ADDF Pipeline Prevention

The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

10/01/2021
12/03/2021

Up to $3,000,000 for clinical trials based on stage and scope of research

– For studies requiring additional support, co-funding from other funding agencies or investors is encouraged

– Payment structure will be negotiated and based on milestone achievements and recruitment

Multi-year Potential for follow-on funding

Yuko Hara, PhD, Director, Aging & Alzheimer’s Prevention
yhara@alzdiscovery.org

Learn More Close

ADDF Pipeline Prevention

The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

05/28/2021
07/30/2021

Up to $3,000,000 for clinical trials based on stage and scope of research

– For studies requiring additional support, co-funding from other funding agencies or investors is encouraged

– Payment structure will be negotiated and based on milestone achievements and recruitment

Multi-year Potential for follow-on funding

Yuko Hara, PhD, Director, Aging & Alzheimer’s Prevention
yhara@alzdiscovery.org

Learn More Close

ADDF Pipeline Prevention

The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

02/05/2021
04/16/2021

Up to $3,000,000 for clinical trials based on stage and scope of research

– For studies requiring additional support, co-funding from other funding agencies or investors is encouraged

– Payment structure will be negotiated and based on milestone achievements and recruitment

Multi-year Potential for follow-on funding

Yuko Hara, PhD, Director, Aging & Alzheimer’s Prevention
yhara@alzdiscovery.org

Learn More Close

Alzheimer’s Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.

PAR-20-309
National Institute on Aging (NIA)
01/05/2021
01/05/2021
02/05/2021

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is 5 years.

Pharmacological Interventions:
Laurie Ryan, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-9350
Email: ryanl@mail.nih.gov

Non-Pharmacological Interventions:
Kristina McLinden, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-9350
Email: mclindenka@mail.nih.gov

Learn More Close

ADDF Neuroimaging and CSF Biomarker Program

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

10/01/2021
12/03/2021

Up to $600,000 based on stage and scope of research.

One year with potential for follow-on funding. Multi-year proposals can be considered.

Meriel Owen, PhD, Assistant Director, Scientific Affairs
mowen@alzdiscovery.org

Learn More Close

ADDF Neuroimaging and CSF Biomarker Program

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

05/28/2021
07/30/2021

Up to $600,000 based on stage and scope of research.

One year with potential for follow-on funding. Multi-year proposals can be considered.

Meriel Owen, PhD, Assistant Director, Scientific Affairs
mowen@alzdiscovery.org

Learn More Close

ADDF Neuroimaging and CSF Biomarker Program

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

02/05/2021
04/16/2021

Up to $600,000 based on stage and scope of research.

One year with potential for follow-on funding. Multi-year proposals can be considered.

Meriel Owen, PhD, Assistant Director, Scientific Affairs
mowen@alzdiscovery.org

Learn More Close

ADDF Program to Accelerate Clinical Trials

The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.

10/01/2021
12/03/2021

Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and recruitment

Multi-year; Potential for follow-on funding

Alessio Travaglia, PhD, Scientific Program Officer
atravaglia@alzdiscovery.org

Learn More Close

ADDF Program to Accelerate Clinical Trials

The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.

05/28/2021
07/30/2021

Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and recruitment

Multi-year; Potential for follow-on funding

Alessio Travaglia, PhD, Scientific Program Officer
atravaglia@alzdiscovery.org

Learn More Close

ADDF Program to Accelerate Clinical Trials

The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.

02/05/2021
04/16/2021

Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and recruitment

Multi-year; Potential for follow-on funding

Alessio Travaglia, PhD, Scientific Program Officer
atravaglia@alzdiscovery.org

Learn More Close

ADDF Drug Development Program

The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.

10/01/2021
12/03/2021

Up to $600,000 based on stage and scope of research.
Payment structure will be negotiated and based on milestone achievements.

One year with potential for follow-on funding. Multi-year proposals can be considered.

Alessio Travaglia, PhD, Scientific Program Officer
atravaglia@alzdiscovery.org

Learn More Close

ADDF Drug Development Program

The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.

05/28/2021
07/30/2021

Up to $600,000 based on stage and scope of research.
Payment structure will be negotiated and based on milestone achievements.

One year with potential for follow-on funding. Multi-year proposals can be considered.

Alessio Travaglia, PhD, Scientific Program Officer
atravaglia@alzdiscovery.org

Learn More Close

ADDF Drug Development Program

The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.

02/05/2021
04/16/2021

Up to $600,000 based on stage and scope of research.
Payment structure will be negotiated and based on milestone achievements.

One year with potential for follow-on funding. Multi-year proposals can be considered.

Alessio Travaglia, PhD, Scientific Program Officer
atravaglia@alzdiscovery.org

Learn More Close

Notice of Change in Application Types Allowed for PAR-19-071 Research on Current Topics in Alzheimer’s Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)

This Notice informs potential applicants that the application types allowed in response to PAR-19-071 Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Not Allowed) have been expanded to include Revision and Resubmission applications. This change is effective as of the July 9, 2020 application due date.

National Institute on Aging (NIA)
Learn More Close

Notice of Change in Application Types Allowed for PAR-19-070 Research on Current Topics in Alzheimer’s Disease and Its Related Dementias (R01 Clinical Trial Optional)

This Notice informs potential applicants that the application types allowed in response to PAR-19-070 Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) have been expanded to include Revision applications. This change is effective as of the July 9, 2020 application due date.

National Institute on Aging (NIA)
Learn More Close

Alzheimer’s Disease Sequencing Project Functional Genomics Consortium (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team-science strategy and apply high-throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimer’s disease and related dementias (AD/ADRD).

National Institute on Aging (NIA)
06/01/2020
06/01/2020
07/01/2020

NIA intends to commit $5 million in FY 2021 to support up to 3 awards. Direct costs should not exceed $1 million per year.

The maximum project period is five years

Alison Yao, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-827-7264
Email:alison.yao@nih.gov

Marilyn Miller, Ph.D.
National Institute on Aging
Telephone: 301-496-9350
Email: millerm@nia.nih.gov

Learn More Close

Prodromal α-Synucleinopathies Consortium (PαSS) (U19 Clinical Trial Optional)

The PαSS U19 seeks to understand and characterize the preclinical/prodromal phase of α-synucleinopathies. The study will recruit a cohort of iRBD subjects and follow them if/until they convert to PD, LBD, or MSA, using standardized psychometric tests, clinical/neurological evaluations, and diagnostic procedures. PαSS will identify changes associated with the earliest manifestations of α-synucleinopathy disease, including biomarkers of disease progression and potential surrogate endpoints. Biomarkers of α-synucleinopathy burden may range from neurophysiology, to changes in biofluid/tissue, to neuroimaging changes. The eventual goal is to find neuroprotective interventions for α-synucleinopathies.

National Institute on Aging (NIA) National Institute of Neurological Disorders and Stroke (NINDS)
05/17/2020
05/17/2020
06/17/2020

Issuing IC and partner components intend to commit an estimated total of $4,275,000 to fund 1 award.

Application budgets are limited to $3 million in direct costs per year.

The maximum project period is 5 years.

Miroslaw (Mack) Mackiewicz, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-594-7636
Email: mirsoslaw.mackiewicz@nih.gov

John Hsiao, MD
National Institute on Aging (NIA)
Telephone: 301-496-9350
Email: jhsiao@mail.nih.gov

Debra Babcock, Ph.D., MD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9964
Email: dbabcock@mail.nih.gov

Learn More Close

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)

The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA RFA-NS-19-044 .

RFA-NS-19-043
National Institute on Aging (NIA) National Institute of Neurological Disorders and Stroke (NINDS)
01/09/2020

The BRAIN Initiative intends to commit $4.0M per year in fiscal years 2020-2023 to fund an estimate of 20 awards per year.

Award budgets are composed of salary and other program-related expenses. See full FOA for details.

The total project period may not exceed 5 years.

For project relevance or scientific questions:
Edmund (Ned) Talley, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1917
Email: BRAINDIVERSITYK99R00@nih.gov

For mechanism or career development questions:
Michelle Jones-London, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-451-7966
Email: BRAINDIVERSITYK99R00@nih.gov

Learn More Close

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)

The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA (RFA-NS-19-043)

RFA-NS-19-044
National Institute on Aging (NIA) National Institute of Neurological Disorders and Stroke (NINDS)
01/10/2020

The BRAIN Initiative intends to commit $4.0M per year in fiscal years 2020-2023 to fund an estimate of 20 awards per year.

Award budgets are composed of salary and other program-related expenses. See full FOA for details.

The total project period may not exceed 5 years.

For project relevance or scientific questions:
Edmund (Ned) Talley, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1917
Email: BRAINDIVERSITYK99R00@nih.gov

For mechanism or career development questions:
Michelle Jones-London, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-451-7966
Email:BRAINDIVERSITYK99R00@nih.gov

Learn More Close

Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program in the Neurosciences (T32 Clinical Trial Not Allowed)

The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (JSPTPN) is an institutional program that supports broad and fundamental research training in the neurosciences. In addition to a broad education in the neurosciences, a key component will be a curriculum that provides a strong foundation in experimental design, statistical methodology and quantitative reasoning. JSPTPN programs are intended to be 2 years in duration and students may only be appointed to this training grant during the first 2 years of their graduate research training. The primary objective is to prepare students to be outstanding scientists equipped to pursue careers in neuroscience.

PAR-20-076
National Institute on Aging (NIA) National Institute on Drug Abuse National Institute of Mental Health National Institute of Neurological Disorders and Stroke (NINDS)
04/26/2020

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets are not limited, but need to reflect the actual needs of the proposed project.

Up to 5 years

Applicants should refer to the (JSPTPN website) for each IC’s scientific/research contact for this NRSA T32 program. Applicants should contact the Chair of the JSPTPN Steering Committee with questions about this FOA or the application itself.

Learn More Close

Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)

This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either through PA-12-064 or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

PAR-20-071
National Institute on Aging (NIA)
01/16/2020

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets may not exceed $499,999 in annual direct costs.

The duration of the R33 award may not exceed 5 years.

Winifred K. Rossi
National Institute on Aging (NIA)
Telephone: 301-496-3836
Email: rossiw@mail.nih.gov

Learn More Close

Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 – Clinical Trial Optional)

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

PAR-20-070
National Institute on Aging (NIA)
01/16/2020

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

The duration of the entire R21/R33 award may not exceed 5 years. The R21 phase may not exceed 2 years of support. The R33 phase may not exceed 3 years of support.

Winifred K. Rossi
National Institute on Aging (NIA)
Telephone: 301-496-3836
Email: rossiw@mail.nih.gov

Learn More Close

Notice of Special Interest: Administrative Supplements for Research on Sex/Gender Influences (Admin Supp Clinical Trial Optional)

The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex and gender influences in human health and illness. Sex and gender are important considerations in many areas of research, including basic biological, psychological, social, and behavioral studies. With continuous interaction between sex and gender, human health is determined by both biology and expression of gender. The most robust experimental designs include consideration of both sex and gender; therefore, applications proposing to investigate the influence of both sex and gender factors are highly encouraged. The proposed research must address at least one objective from the five strategic goals of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women".

NOT-OD-20-049
National Institute on Aging (NIA) National Institute of Neurological Disorders and Stroke (NINDS)

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project.

The project and budget periods must be within the currently approved project period for the existing parent award.

For any scientific or research-related questions on this administrative supplement notice please contact the Program Officer listed on the NoA of the most recent parent award.

Learn More Close

Notice of Special Interest: Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)

The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting health disparities among women in the US who are underrepresented, understudied, and underreported (U3) in biomedical research. The proposed research must address at least one objective from the strategic goals 1, 2, or 3 of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women."

NOT-OD-20-048
National Institute on Aging (NIA) National Institute of Neurological Disorders and Stroke (NINDS)

$2,000,000 is expected to be available annually for funding this program. The budget should not exceed $140,000 direct costs for the administrative supplement per year. In addition to the direct cost, applicable F&A (indirect) cost can also be requested.

The application budget is limited to one year only. Supplements may provide support above the dollar limits of the funding opportunity announcement of the parent grant award.

Rajasri Roy Ph.D., MPH
Office of Research on Women’s Health (ORWH)
Telephone: 301-451-0993
Email: rajasri.roy@nih.gov

Learn More Close

Notice of Participation of the National Institute on Aging (NIA) in PAR-19-343 Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent CT Not Allowed)

NIA participates in NIH-wide programs to increase diversity in the research workforce. The goal of this FOA is to help outstanding postdoctoral researchers who are considered under-represented minority in science to transition into independent, tenure-track or equivalent faculty positions. NIA welcomes applications in all fields of aging research, including basic science, diseases and disabling conditions of aging, the social and behavioral consequences of an aging society, and topics in between. A particular priority of NIA at the moment is research on Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).

NOT-AG-20-009
National Institute on Aging (NIA)
01/12/2020

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Salary Support: NIA will provide K99 salary support commensurate with the applicant institution’s salary structure for persons of equivalent qualifications, experience, and rank for up to $75,000 plus fringe benefits per year.

Research Support: NIA will provide up to $25,000 research support per year for the K99 phase of the award.

Other Program-Related Expenses: TRAVEL: The application may request up to $2,500 annually to defray the cost of participation in professional meetings (excluding MOSAIC associated meetings, the costs of which will be covered by the UE5 awardees).

The total project period may not exceed 5 years.

Shahrooz Vahedi, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-9322
Email: shahrooz.vahedi@nih.gov

Learn More Close

Improving Quality of Care and Patient Outcomes During Care Transitions (R01)

This Funding Opportunity Announcement (FOA) invites R01 grant applications for funding health services research that improves the quality of care and patient outcomes during transitions of care. The purpose of this FOA is to support large-scale research projects that rigorously test promising interventions aimed at improving communication and coordination during care transitions.

This FOA is focused on three research areas of interest.

  • Care transitions between primary care, acute care, and specialty providers
  • Care transitions between different institutional care settings
  • Care transitions with a focus on patients, their families and communities
Agency for Healthcare Research and Quality
12/06/2019

The number of awards is contingent upon the submission of a sufficient number of meritorious applications and the availability of funds. Future year funding will depend on funding availability.

The total costs (direct and indirect) for a project awarded under this FOA will not exceed $400,000 in any given year and $2 million for the entire project period.

The project period may not exceed 5 years.

CDR Derrick L. Wyatt
Agency for Healthcare Research and Quality
Center for Evidence and Practice Improvement (CEPI)
Division of Health Information Technology
Telephone: 301-427-1506
Email: DigitalHealthcareResearch@ahrq.hhs.gov (preferred method of contact)

Learn More Close

Notice of Special Interest: Alzheimer’s-focused administrative supplements for NIH grants that are not focused on Alzheimer’s disease

The participating Institutes and Centers (ICs) are inviting applications to expand existing awards that are not currently focused on Alzheimer’s disease and its related dementias (AD/ADRD)—frontotemporal dementia, Lewy body dementia, vascular cognitive impairment with dementia, and multiple etiology dementias—to allow the research to develop such a focus. Active awards with project end dates in FY 2021 or later are eligible.

National Institute on Aging (NIA) National Institute of Neurological Disorders and Stroke (NINDS)
03/06/2020

See NIH webpage for this notice

Learn More Close

Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional)

This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions.

PAR-19-374
National Institute on Aging (NIA)
09/28/2019

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is 5 years.

Sanoj Suneja, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-402-7710
Email: sunejas@mail.nih.gov

Learn More Close

Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Systems Biology (R03 Clinical Trial Not Allowed)

This Small Research Grant Program (R03) will support important and innovative system biology projects in which more scientific insight is needed to improve the prevention, diagnosis, treatment, and care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The overall goal of this R03 program is (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise.

PAS-19-393
National Institute on Aging (NIA)
01/16/2020

NIH intends to fund an estimated 12 awards for this FOA and its companions, corresponding to a total of $1.8 million, for fiscal year 2020. Future year amounts will depend on annual appropriations.

Applications may request budgets of up to $100,000 in direct costs per year for up to two years.

The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Alison Yao, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-9350
Email: alison.yao@nih.gov

Learn More Close

Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Archiving and Leveraging Existing Data Sets for Analyses (R03 Clinical Trial Not Allowed)

This Small Research Grant (R03) will support important and innovative projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this FOA will support archiving and leveraging existing data sets for analyses of projects covering a wide array of topics relating to AD/ADRD. The overall goal of this FOA is (i) to encourage the next generation of U.S. researchers to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise.

PAS-19-391
National Institute on Aging (NIA)
01/16/2020

NIH intends to fund an estimated 12 awards for this FOA and its companions, corresponding to a total of $1.8 million, for fiscal year 2020. Future year amounts will depend on annual appropriations.

Applications may request budgets of up to $100,000 in direct costs per year for up to two years.

The scope of the project should determine the project period. The maximum project period is 2 years.

Partha Bhattacharyya, Ph.D.
Division of Behavioral and Social Research
National Institute on Aging (NIA)
Telephone: 301-496-3136
Email: bhattacharyyap@mail.nih.gov

Learn More Close

Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Basic Science (R03 Clinical Trials Not Allowed)

This Small Research Grant (R03) will support important and innovative projects focused on basic science approaches to elucidate neurodegenerative mechanisms/pathways of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Proposed projects should ultimately aim to improve the prevention, diagnosis, treatment, and/or care for individuals with AD/ADRD. The program seeks (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise.

PAS-19-392
National Institute on Aging (NIA)
01/16/2020

NIH intends to fund an estimated 12 awards for this FOA and its companions, corresponding to a total of $1.8 million, for fiscal year 2020. Future year amounts will depend on annual appropriations.

Applications may request budgets of up to $100,000 in direct costs per year for up to two years.

The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Lisa Opanashuk, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-807-5422
Email: lisa.opanashuk@nih.gov

Learn More Close

Aging Research Dissertation Awards to Increase Diversity (R36 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to provide dissertation awards in all areas of research within NIA’s strategic priorities to increase the diversity of the scientific research workforce engaged in research on aging and aging-related health conditions.

PAR-19-394
National Institute on Aging (NIA)
01/16/2020

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

This FOA allows for budget requests to cover, per year, a salary consistent with the current fiscal year National Research Service Award (NRSA) predoctoral stipend level (https://grants.nih.gov/training/nrsa.htm#policy) and up to $20,000 for additional expenses such as fringe benefits (including health insurance for self and family members), travel to scientific meetings, and dissertation research costs in accordance with institutional policies. With the exception of costs associated with the dissertation (i.e., dissertation credits), no funds may be used to pay tuition or fees.

Support is provided for up to two years.

Shahrooz Vahedi, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-9322
Email:shahrooz.vahedi@nih.gov

Learn More Close

NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)

The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist.

PAR-20-021
National Institute of Neurological Disorders and Stroke (NINDS)
01/11/2020

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Award budgets are composed of stipends, tuition and fees, and institutional allowance.

Individuals may receive up to 3 years of aggregate Kirschstein-NRSA support at the postdoctoral level, including any combination of support from institutional training grants (e.g., T32) and an individual fellowship award.

Stephen Korn, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-4188
Email: korns@ninds.nih.gov

Learn More Close

Leadership Award for Alzheimer’s Disease and Related Dementias Research (R35 Clinical Trial Not Allowed)

NIA is seeking applications from investigators looking to enhance their research programs to address selected NIH Alzheimer's Disease and Related Dementias Research Implementation Milestones. Investigators will be provided protected time to produce a program of investigation specific to selected goals/milestones. Investigators and their institutions will also be expected to advance more junior researchers' capacity to address selected goals/milestones.

RFA-AG-21
National Institute on Aging (NIA)
05/19/2020
05/19/2020
06/19/2020

NIA intends to commit $5 million in FY 2021 to fund 8-10 awards.

Applicants may request up to $600,000 in directs costs per year. Investigators are encouraged to request what is well justified for their research program. The award amount will be determined by NIA and commensurate with current NIA support of the PD/PI.

Applications may request a maximum project period of five years.

Cerise Elliott, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-9350
Email: elliottce@nih.gov

Learn More Close

NINDS Postdoctoral Mentored Career Development Award (K01 No Independent Clinical Trial Allowed)

The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program.

PAR-20-049
National Institute of Neurological Disorders and Stroke (NINDS)
01/12/2020

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Award budgets are composed of salary and other program-related expenses.

The total project period may not exceed 48 months.

Stephen Korn, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Email: korns@ninds.nih.gov

Learn More Close

Social Epigenomics Research Focused on Minority Health and Health Disparities (R01-Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate human epigenomic investigations focused on identifying and characterizing the mechanisms by which social experiences at various stages in life, both positive and negative, affect gene function and thereby influence health trajectories or modify disease risk in racial/ethnic minority and other health disparity populations.

PAR-19-372
National Human Genome Research Institute (NHGRI) National Institute on Aging (NIA) National Institute on Minority Health and Health Disparities (NIMHD)
10/06/2019

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 5 years

Rina Das, PhD
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-496-3996
Email: dasr2@mail.nih.gov

Lucia Hindorff, Ph.D.
National Human Genome Research Institute
Phone: 240-271-1509
Email: hindorffl@mail.nih.gov

Amelia Karraker, PhD
National Institute on Aging (NIA)
Telephone: 301-496-3138
Email: Amelia.Karraker@nih.gov

Learn More Close

NINDS Postdoctoral Mentored Career Development Award (K01 Clinical Trial Required)

The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program.

PAR-20-050
National Institute of Neurological Disorders and Stroke (NINDS)
01/12/2020

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Award budgets are composed of salary and other program-related expenses.

The total project period may not exceed 48 months.

Stephen Korn, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Email: korns@ninds.nih.gov

Learn More Close

Notice of Intent to Publish a Funding Opportunity Announcement for Impact of Alcohol on the Onset and Progression of Alzheimer’s Disease and Its Related Dementias (R01 – Clinical Trial Optional)

National Institute on Alcohol Abuse and Alcoholism (NIAAA) in partnership with the National Institute on Aging (NIA) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to investigate mechanisms underlying the influence of alcohol on the onset and progression of Alzheimer’s disease and its related dementias.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects.

The FOA is expected to be published in Fall 2019 with an expected application due date in Spring 2020.

This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

OT-AA-19-026
National Institute on Aging (NIA) National Institute on Alcohol Abuse and Alcoholism (NIAAA)

$3 million for 6-8 awards

$250,00 direct costs/year

Changhai Cui, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
301-443-1678
Email: changhai.cui@nih.gov

Bradley C. Wise, Ph.D.
National Institute of Aging (NIA)
Telephone:301-496-9350
Email: WiseB@nia.nih.gov

Learn More Close

Neurotoxin Exposure Treatment Parkinson’s Program, Synergistic Idea Award

The NETP Program Synergistic Idea Award supports new ideas that represent synergistic approaches to neurotoxin exposure and treatment-related Parkinson’s disease research involving two to four Principal Investigators (PIs) at the Assistant Professor (or equivalent) level or above. These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in neurotoxin exposure and treatment-related Parkinson’s research. This award is designed to support both new and pre-existing partnerships and encourages participation of PIs from other research fields.

Department of Defense
08/18/2020
09/16/2020

The NETP Program Synergistic Idea Award mechanism is being offered for the first time in FY20. The CDMRP expects to allot approximately $6M to fund approximately two Synergistic Idea Award applications.

The anticipated total costs budgeted for the entire period of performance for an FY20 NETP Program SIA will not exceed $3M.

The maximum period of performance is 4 years.
Learn More Close

Neurotoxin Exposure Treatment Parkinson’s Program: Early Investigator Research Award

The NETP Program EIRA supports neurotoxin exposure and treatment-related Parkinson’s disease research opportunities for investigators in the early stages of their careers, under the guidance of a designated Mentor(s). The Early Investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of Parkinson’s disease research; however, the PI is not required to have previous Parkinson’s disease research experience. Applications must include at least one Mentor, appropriate to the proposed research project, who has experience in Parkinson’s disease research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a neurotoxin exposure and treatment-related Parkinson’s disease researcher.

Department of Defense
09/16/2020

The CDMRP expects to allot approximately $1.6M to fund approximately four Early Investigator Research Award applications.

The anticipated total costs budgeted for the entire period of performance for an FY20 NETP Program EIRA will not exceed $400,000.

The maximum period of performance is 2 years.
Learn More Close

Neurotoxin Exposure Treatment Parkinson’s Program: Investigator-Initiated Research Award

The NETP Program IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to neurotoxin exposure and treatment-related Parkinson’s research. This award mechanism supports the full spectrum of research from basic science through clinical research.

Department of Defense
09/16/2020

The CDMRP expects to allot approximately $7.2M to fund approximately six IIRA applications.

The anticipated total costs budgeted for the entire period of performance will not exceed $1.2M.

The maximum period of performance is 3 years.
Learn More Close

Notice of Intent to Publish a Funding Opportunity Announcement for NINDS Morris K. Udall Centers of Excellence for Parkinson’s Disease Research (P50 Clinical Trial Optional)

The National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for the Morris K. Udall Centers of Excellence for Parkinson's Disease Research program. The overarching goal of this program is to establish a network of specialized Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinson’s disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Udall Centers also serve as local resources by providing research career enhancement activities for Center investigators and periodic outreach to the PD patient/advocacy community

Applicants to the Udall Centers program will identify and address an overall research theme that defines a critical challenge in PD research. The Center theme, proposed research projects, and associated cores will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such directly address the identified PD research challenge. Programmatic requirements of this FOA include: three or more Research Projects, including a dedicated Udall Catalyst project led by a junior investigator; an Administrative Core; at least one integrated Research Core that is essential to and accelerates the progress of two or more Research Projects; a mission statement for career enhancement of Center investigators, and a plan for periodic outreach to the local patient/advocacy community, including specific outreach events to convey Center research advances.

National Institute of Neurological Disorders and Stroke (NINDS)
06/25/2020
09/25/2020

The NINDS intents to commit up to $6,750,000 total costs in fiscal year (FY) 2021. NINDS expect to fund 3 awards, contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Applicants may request up to $1,000,000 direct costs per year with the following exception: applications containing a translational project and/or clinical component (i.e. clinical research project plus a clinical core) may request up to $1,500,000 direct costs per year. Application budgets must justify and reflect the actual needs of the proposed project.

The project period will be five years.

Beth-Anne Sieber, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
(301) 496-5680
Beth-Anne.Sieber@nih.gov

Learn More Close

Notice of Intent to Publish a Funding Opportunity Announcement for NINDS Exploratory Grant Program in Parkinson’s Disease Research (P20- Clinical Trial Optional) (P20 Clinical Trial Optional)

The goal of this program is to formalize new interdisciplinary teams to address critical gaps in PD research and establish a foundation of research discovery leading directly to an NINDS Morris K. Udall Center of Excellence for PD Research (P50) application.

National Institute of Neurological Disorders and Stroke (NINDS)
06/25/2020
09/25/2020

The NINDS intends to commit up to $1,800,000 in FY2021.The number of expected awards is 4, contingent upon NIH appropriations and the submission of sufficiently meritorious applications.

Application budgets are limited to $300,000 direct costs per year (exclusive of facilities and administrative costs of subcontracts with collaborating institutions). Budget requests should reflect the actual needs of the proposed project.

The Exploratory Grant will provide up to two years of support.

Beth-Anne Sieber, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
(301) 496-5680
Beth-Anne.Sieber@nih.gov

Learn More Close

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp – Clinical Trial Not Allowed)

Funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, post-doctorates, and eligible investigators from underrepresented backgrounds, including those from groups that have been shown to be nationally underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

National Institute on Aging (NIA) Office of The Director, National Institutes of Health (OD) National Institute of Neurological Disorders and Stroke (NINDS)
04/21/2020

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project. Direct costs for individual administrative supplements vary from less than $5,000 to more than $100,000 depending on the career level of the candidate. Administrative supplements end with the currently funded competitive cycle of the parent grant. Budget requests may also be limited by the awarding IC.

The project and budget periods must be within the currently approved project period for the existing parent award.
Learn More Close

Independent Scientist Award (Parent K02 – Independent Clinical Trial Required)

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.

National Institute on Aging (NIA) Office of The Director, National Institutes of Health (OD) National Institute of Neurological Disorders and Stroke (NINDS)
05/12/2020

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Award budgets are composed of salary and other program-related expenses. The participating NIH Institutes and Centers will provide salary and fringe benefits for the award recipient (see Table of IC-Specific Information, Requirements and Staff Contacts). Further guidance on budgeting for career development salaries is provided in the SF424 (R&R) Application Guide. See also NOT-OD-17-094.

The total project period may not exceed 5 years.
Learn More Close

Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.

This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

National Institute on Aging (NIA) Office of The Director, National Institutes of Health (OD) National Institute of Neurological Disorders and Stroke (NINDS)
05/12/2020

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Award budgets are composed of salary and other program-related expenses. The participating NIH Institutes and Centers will provide salary and fringe benefits for the award recipient (see Table of IC-Specific Information, Requirements and Staff Contacts). Further guidance on budgeting for career development salaries is provided in the SF424 (R&R) Application Guide. See also NOT-OD-17-094.

The total project period may not exceed 5 years.
Learn More Close

Notice of Special Interest: Dementia Care Workforce for Those Living with Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD)

This Notice of Special Interest (NOSI) is intended to promote behavioral and social research on the dementia care workforce and the impact on outcomes for persons living with Alzheimer's disease or Alzheimer's disease-related dementia (AD/ADRD) and their families. Broad areas of interest include (1) how economic and policy factors drive the composition and quality of the dementia care workforce; (2) demographic and familial factors that influence demand for and supply of dementia care workers; (3) training and certification effects on quality and retention of dementia care workers; and (4) the development of data resources required to study these issues.

This notice applies to due dates on or after July 9, 2020 and subsequent receipt dates through November 13, 2021.
Submit applications for the initiative using one of the following funding opportunity announcements (FOAs) or any reissue of these announcements through the expiration date of this notice.

PAR-19-070 Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
PAR-19-071 Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)

NOT-AG-20-026
National Institute on Aging (NIA)
07/09/2020
11/13/2020

John Phillips, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-3136
Email: john.phillips@nih.gov

Elena Fazio, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-3136
Email: elena.fazio@nih.gov

Learn More Close

Development of Standard Core Clinical Outcomes Assessments (COAs) and Endpoints (UG3/UH3 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for UG3/UH3 cooperative agreements to support the development of a publicly available core set(s) of COAs and their related endpoints for specific disease indications or for disease impacts that span multiple rare diseases of similar phenotypes.

The standard core set(s) can include different types of COAs (i.e. patient-reported outcome [PRO], clinician-reported outcome [ClinRO], observer-reported outcome [ObsRO], performance outcome [PerfO] instruments) and their related endpoints that assess a minimum list of impacts that matter most to patients, are likely to demonstrate change (including differences in trial arms related to disease burden, treatment burden, and if applicable, physical function) and should be reported in a clinical trial. A standard core set might be relevant across several disease populations or subgroups or be focused on attributes of a specific disease (a disease-specific or generic instrument that can adapted and applied more broadly across disease areas or across age groups).

The UG3/UH3 Phase Innovation Award Cooperative Agreement involves 2 phases. The UG3 phase will provide funding for 1 to 2 years to conduct planning activities. The UH3 phase will provide funding for 3 to 4 years to projects that successfully complete the planning activities and reach the projected milestones set in the UG3 phase.

RFA-FD-21-004
Food and Drug Administration
07/14/2020
08/21/2020

The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for four (4) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory awardee performance.

FDA/CDER intends to commit up to $4,200,000 total for fiscal year 2021 to fund up to three (3) awards in support of this grant program.

Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs (direct and indirect):
UG3 (up to 2 years):

Combined years: up to $1,400,000 total costs/per award

It is up to the applicant to determine the number of years and budget for the UG3 phase. The application should provide justification for the number of years and budget split among the years if the UG3 phase is anticipated to take more than 1 year.

UG3 (up to 4 years):

Combined years: up to $2,700,000 total costs/award

It is up to the applicant to determine the number years and budget for the UH4 phase. The application should provide justification for the number of years for the UH3 phase and budget split among the years.

The scope of the proposed project should determine the project period. The UG3 phase is limited to up to two years and the UH3 phase can request up to four years of support. The total project period for an application submitted in response to this FOA may not exceed five (5) years.

Robyn Bent
Center for Drug Evaluation and Research (CDER)
Telephone: 301-796-9171
Email: robyn.bent@fda.hhs.gov

Learn More Close

Notice of Special Interest: Fundamental and Translational Research on Decision Making in Aging and/or Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD)

This Notice of Special Interest (NOSI) underscores NIA’s continued commitment to research that seeks to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), and AD-related dementias (ADRD). Research is sought that characterizes the extent to which behavioral, psychological, and neural processes involved in decision making are differentially impacted in normal aging, MCI, and AD/ADRD. Investigations that target the influence of social factors on decision making or other factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse are of particular interest.

This NOSI also encourages preclinical and applied research on decision making that may facilitate the design of decision-supportive interventions for midlife and older adults with and without MCI and AD/ADRD. Specific opportunities include the development of decision-support interventions to leverage cognitive, emotional, social, and motivational strengths of these populations; tools to assess decisional capacities; strategies for simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices (e.g., power of attorney, living wills, etc.). The use of animal models to explore the neural basis of affective, cognitive, social, and motivational parameters as they relate to age-related changes in decision making is also invited.

National Institute on Aging (NIA)

Luke Stoeckel, Ph.D.
National Institute on Aging (NIA)
Telephone: 202-570-9388
Email: luke.stoeckel@nih.gov

Molly V. Wagster, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-594-7768
Email: wagsterm@nia.nih.gov

Learn More Close

NINDS Exploratory Grant Program in Parkinson’s Disease Research (P20- Clinical Trial Optional

This Funding Opportunity Announcement (FOA) invites Exploratory Grant (P20) applications for the planning and initiation of collaborative efforts to advance Parkinson's Disease (PD) research. The goal of this program is to formalize new collaborative directions and/or novel interdisciplinary teams to address critical gaps in PD research and to establish a rigorous foundation of research discovery leading directly to an NINDS Morris K. Udall Center of Excellence (P50) application. Through this mechanism, the NINDS seeks to develop synergistic, proof-of-concept research efforts around investigator-defined gaps in PD research and support collaborative teams to develop a research plan, construct an effective administrative organization, create standardized policies/procedures, and gather rigorous preliminary data in support of novel ideas to address urgent needs and emergent issues in PD research. The Exploratory Grant theme and proposed research feasibility projects will inform the etiology, pathogenesis, or treatment of PD; investigations on related synucleinopathies may be included if such directly address the identified PD research gap.

RFA-NS-21-002
National Institute of Neurological Disorders and Stroke (NINDS)
08/28/2020
09/28/2020

The NINDS intends to fund up to 4 awards in FY2021, corresponding to a total of $1.2 million in direct costs. Only one Exploratory Grant will be awarded per applicant institution.

Application budgets are limited to $300,000 direct costs per year (exclusive of facilities and administrative costs of subcontracts with collaborating institutions).

The maximum project period is to 2 years

Beth-Anne Sieber, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-5680
Email: Beth-Anne.Sieber@nih.gov

Learn More Close

NINDS Morris K. Udall Centers of Excellence for Parkinson’s Disease Research (P50 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites applications for the Morris K. Udall Centers of Excellence for Parkinson’s Disease Research program. The overarching goal of this program is to support specialized research Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinson’s disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Applicants will identify an overall research theme that directly addresses a critical challenge in PD research. The Center theme, proposed research projects, and associated cores will inform the etiology, pathogenesis, or treatment of PD; investigations on related synucleinopathies may be included if such directly address the identified PD research challenge.

RFA-NS-21-001
National Institute of Neurological Disorders and Stroke (NINDS)
08/28/2020

The NINDS intents to commit up to $6,750,000 total costs in fiscal year (FY) 2021.

Applicants may request up to $1,000,000 direct costs per year with the follow exception: applications containing a translational project and/or clinical component (i.e. clinical research project plus a clinical core) may request up to $1,500,000 direct costs per year.

The project period is limited to 5 years

Beth-Anne Sieber, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-5680
Email: Beth-Anne.Sieber@nih.gov

Learn More Close

Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional)

This FOA invites applications that employ integrative experimental and analytical approaches engaging basic and translational/clinical research aimed at developing a comprehensive understanding of the impact of sex differences on the trajectories of brain aging and disease, phenotypes of AD and AD-related dementias (ADRD) risk, individualized prevention, and responsiveness to pharmacologic and non-pharmacologic interventions.

National Institute on Aging (NIA)
10/10/2020
10/10/2020
11/10/2020

NIA intends to commit $5.5 million in FY 2021 to support 2-5 awards.

Annual direct costs are capped at $750,000.

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Jean Yuan, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-9350
Email: yuanx4@mail.nih.gov

Learn More Close

Solicitation of Nominations for the 2021 National Institute of Neurological Disorders and Stroke (NINDS) Landis Award for Outstanding Mentorship

To recognize the crucial role great mentors play in the development of future leaders in neuroscience, the National Institute of Neurological Disorders and Stroke (NINDS) created the Landis Award for Outstanding Membership. This award provides $100,000.00 (direct costs) to up to five (5) faculty members, who are considered to be outstanding mentors and trainers, to help foster the research career development of additional students and post-doctorates.

Nominations for the NINDS Landis Mentor Award will be accepted ONLY from current and former trainees of the nominated individual.

NOT-NS-20-093
National Institute on Aging (NIA)
12/15/2020

Up to 5 awards per year

Each award is $100,000 direct cost, in the form of an administrative supplement

Contact: Stephen Korn
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-4188
Email: korns@ninds.nih.gov

Learn More Close

Transition to Aging Research for Predoctoral Students (F99/K00)

NIA invites outstanding graduate students from a wide range of broad research areas including, but not limited to, statistics, neuroscience, physics, immunology, microbiology, informatics, data sciences, psychology, (bio)behavioral science, anthropology, demography, sociology, social epidemiology, economics, public health, and engineering who are interested in receiving aging-related postdoctoral training to apply for this award.

The purpose of the Transition to Aging Research Award for Predoctoral Students is to increase, retain, and diversify the pool of trainees in aging and geriatric research.

RFA-AG-21-022
National Institute on Aging (NIA)
09/22/2020
10/22/2020

NIA intends to commit $450,000 in FY 2021 to fund 7-10 awards.

Award budgets are composed of stipends, tuition and fees, and institutional allowance

Individuals may receive up to 5 years of aggregate Kirschstein-NRSA support at the predoctoral level (up to 6 years for dual degree training, e.g., MD/PhD), and up to 3 years of aggregate Kirschstein-NRSA support at the postdoctoral level, including any combination of support from institutional training grants (e.g., T32) and an individual fellowship award.
Learn More Close

Extramural Loan Repayment Program for Health Disparities Research (LRP-HDR)

The objective of the LRP-HDR is to recruit and retain highly qualified health professionals into research careers that focus on minority health disparities or other health disparities.

The NIH invites qualified health professionals who contractually agree to engage in NIH mission-relevant research for an average of at least 20 hours each week for at least two years, initially, to apply for an award in the Extramural LRP. The Extramural LRP repays up to $50,000 annually of a researcher's qualified educational debt in return for a commitment to engage in NIH mission-relevant research at a domestic, nonprofit, or government entity. Research funding from NIH is not required to participate in the Extramural LRP. LRP awards are based on an applicant's potential to build and sustain a research career.

NOT-OD-20-137
Office of The Director, National Institutes of Health (OD)
09/01/2020
11/20/2020

The NIH intends to commit approximately $6 million annually to fund LRP-HDR awards.

The Extramural LRP repays up to $50,000 annually of a researcher’s qualified educational debt in return for a commitment to engage in NIH mission-relevant research at a domestic, nonprofit, or government entity.

2 year commitment

Additional detailed information about the NIH Loan Repayment Programs is provided at www.lrp.nih.gov/about_the_programs/index.aspx. Applicants are strongly encouraged to discuss their career interests with an NIH Institute or Center scientific liaison provided at this site: www.lrp.nih.gov/contact_us/contact_list.aspx.

Learn More Close

Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds (LRP-IDB)

The objective of the LRP-IDB is to recruit and retain highly qualified health professionals from disadvantaged backgrounds into clinical research careers. The emphasis on clinical research and individuals from disadvantaged backgrounds highlights the need for the involvement of a cadre of competent health professionals in clinical research.

The NIH invites qualified health professionals who contractually agree to engage in NIH mission-relevant research for an average of at least 20 hours each week for at least two years, initially, to apply for an award in the Extramural LRP. The Extramural LRP repays up to $50,000 annually of a researcher's qualified educational debt in return for a commitment to engage in NIH mission-relevant research at a domestic, nonprofit, or government entity. Research funding from NIH is not required to participate in the Extramural LRP. LRP awards are based on an applicant's potential to build and sustain a research career.

NOT-OD-20-134
National Institute on Aging (NIA) National Institute of Neurological Disorders and Stroke (NINDS)
09/01/2020
09/18/2020
12/26/2020

The NIH intends to commit approximately $1 million annually to fund LRP-IDB awards.

The Extramural LRP repays up to $50,000 annually of a researcher’s qualified educational debt in return for a commitment to engage in NIH mission-relevant research at a domestic, nonprofit, or government entity.

2 year commitment

Additional detailed information about the NIH Loan Repayment Programs is provided at www.lrp.nih.gov/about_the_programs/index.aspx.

Applicants are strongly encouraged to discuss their career interests with the NIMHD scientific liaison, whose contact information is provided on this web page: www.lrp.nih.gov/contact_us/contact_list.aspx.

Learn More Close

Extramural Loan Repayment Program for Clinical Researchers (LRP-CR)

The objective of the LRP-CR is to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers.

The NIH invites qualified health professionals who contractually agree to engage in NIH mission-relevant research for an average of at least 20 hours each week for at least two years, initially, to apply for an award in the Extramural LRP. The Extramural LRP repays up to $50,000 annually of a researcher's qualified educational debt in return for a commitment to engage in NIH mission-relevant research at a domestic, nonprofit, or government entity. Research funding from NIH is not required to participate in the Extramural LRP. LRP awards are based on an applicant's potential to build and sustain a research career.

NOT-OD-20-133
National Institute on Aging (NIA) National Institute of Neurological Disorders and Stroke (NINDS)
09/01/2020
11/20/2020

The NIH intends to commit approximately $50 million annually to fund LRP-CR awards.

The Extramural LRP repays up to $50,000 annually of a researcher’s qualified educational debt in return for a commitment to engage in NIH mission-relevant research at a domestic, nonprofit, or government entity.

2 year commitment

Additional detailed information about the NIH Loan Repayment Programs is provided at www.lrp.nih.gov/about_the_programs/index.aspx. Applicants are strongly encouraged to discuss their career interests with an NIH Institute or Center scientific liaison provided at this site: www.lrp.nih.gov/contact_us/contact_list.aspx.

Learn More Close